Filing Details

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

---

 

 

  *Based upon information contained in the Form 10-K for the year ended December 31, 2021 filed by BioRestorative Therapies, Inc (the "Company") with the Securities and Exchange Commission (the "SEC") on March 30, 2022, there were 3,626,603 shares of the Company's common stock (the "Shares") issued and outstanding as of March 28, 2022. 

This Amendment No. 7 to Schedule 13D reflects the aggregate number of Shares beneficially owned by the Reporting Person and includes (i) 251,853 Shares owned directly by the Reporting Person; (ii) 316,972 Shares owned indirectly by the Reporting Person through Fleetco, Inc. of which he is a 93% shareholder; (iii) 250 Shares underlying warrants held by the Reporting Person with an exercise price of $120 per Share and an expiration date of February 19, 2024; (iv) 276 Shares underlying warrants held by the Reporting Person with an exercise price of $120 per Share and an expiration date of May 7, 2024; and (v) 833 Shares underlying a warrant held by the Reporting Person with an exercise price of $120 per Share and an expiration date of October 6, 2024.  As a result of the foregoing, as of the filing date of this Amendment No. 7 to Schedule 13D, the Reporting Person may be deemed to beneficially own 570,184 Shares, or 15.7% of the Shares issued and outstanding as of March 28, 2022.  Percent of class assumes the exercise of all of the Warrants held by the Reporting Person for the acquisition of 1,359 Shares.

Item 1.  Security and Issuer.

This statement relates to the shares of Common Stock, par value $.0001 per share ("Shares" or the "Common Stock"), of BioRestorative Therapies, Inc., a Delaware corporation (the "Company").  The address of the principal executive offices of the Company is 40 Marcus Drive, Suite One, Melville, New York  11747.

Item 2.  Identity and Background.

a.

Name

Dale Broadrick

b.	Residence or Business Address

3003 Brick Church Pike

Nashville, Tennessee  37207

c.	Occupation

The Reporting Person is a private investor.

d.	Convictions

During the last five years, the Reporting Person, to the best of is knowledge, has not been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).

e.	Civil Judgments

During the last five years, the Reporting Person, to the best of his knowledge, has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

f.	Citizenship

The Reporting Person is a citizen of the United States of America.

Item 3.  Source or Amount of Funds or Other Consideration.

See Item 4.

Item 4.  Purpose of Transaction.

The Shares were acquired, and are being held, for investment purposes.  The Reporting Person believes that the Common Stock of the Company is significantly undervalued and does not reflect the value of its business opportunity and its intellectual property.

The Reporting Person may purchase additional shares of Common Stock from time to time depending upon price, market conditions, availability of funds, evaluation of other investment opportunities, and other factors.  The Reporting Person has no present intention to sell any shares of Common Stock, although the Reporting Person could determine from time to time, based upon the same factors listed above for purchases, to sell some or all of the shares of Common Stock held by the Reporting Person.

The Reporting Person does not have any plans or proposals that would result in any of the actions or transactions described in clauses (a) through (j) of Item 4 of Schedule 13D, except as set forth above.

a.	An Acquisition or Disposition

b.	A Corporate Transaction:

c.	A Sale or Transfer of Assets:

d.	A Change in Board of Directors:

e.	A Change in Capitalization:

f.	Other Material Change:

g.	Changes to Charter

h.	Causing Delisting:

i.	Termination of Registration:

j.	A Similar Action:

 

Item 5.  Interest in Securities of the Issuer.

a.

State the aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by each person named in Item 2.

As of April 5, 2022 the Reporting Person beneficially owned 570,184 shares of Common Stock of the Company, including 1,359 shares of Common Stock of the Company issuable upon the exercise of currently exercisable warrants.  As of such date, the Reporting Person beneficially owned 15.7% of the outstanding Common Stock of the Company, based on there being 3,626,603 shares of Common Stock of the Company outstanding as of March 28, 2022, as set forth in the Company's Form 10-K for the year ended December 31, 2021 filed with the SEC on March 30, 2022 and presently exercisable warrants issued to the Reporting Person for the purchase of an aggregate of 1,359 shares of Common Stock of the Company.

b.

For each person named, indicate the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.

As of April 5, 2022, the Reporting Person had sole voting power and sole dispositive power with respect to 570,184 shares of Common Stock.

c.

Describe any transactions that were effected during the past sixty days or since the most recent filing of Schedule 13D.

Since the filing of Amendment No. 6 to Schedule 13D on March 29, 2022, the Reporting Person acquired, directly or indirectly, the following securities of the Company:

d.

If any other person is known to have the right to receive or direct dividends or proceeds from the sale of securities, a statement to that effect should be included:

e.

The date the reporting person ceased to be the beneficial owner of more than five percent of the class of securities: (If applicable)

 

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Except with respect to the warrants held by the Reporting Person for the purchase of an aggregate of 1,359 shares of Common Stock of the Company, the Reporting Person does not have any contract, arrangement, understanding or relationship (legal or otherwise) with any person with respect to any securities of the Company, including but not limited to the transfer of voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

Item 7.  Material to Be Filed as Exhibits.

 

 None.

 

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 6, 2022

 

 

 

---